Logo image of CSBR

CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis

USA - NASDAQ:CSBR - US15870P3073 - Common Stock

6.487 USD
-0.07 (-1.11%)
Last: 10/17/2025, 4:04:02 PM
Fundamental Rating

5

Overall CSBR gets a fundamental rating of 5 out of 10. We evaluated CSBR against 56 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of CSBR while its profitability can be described as average. CSBR has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year CSBR was profitable.
In the past year CSBR had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

CSBR has a better Return On Assets (9.66%) than 87.50% of its industry peers.
CSBR has a Return On Equity of 84.15%. This is amongst the best in the industry. CSBR outperforms 98.21% of its industry peers.
Looking at the Return On Invested Capital, with a value of 30.30%, CSBR belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
Industry RankSector Rank
ROA 9.66%
ROE 84.15%
ROIC 30.3%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

With a decent Profit Margin value of 5.19%, CSBR is doing good in the industry, outperforming 67.86% of the companies in the same industry.
CSBR's Profit Margin has improved in the last couple of years.
CSBR has a better Operating Margin (5.29%) than 60.71% of its industry peers.
In the last couple of years the Operating Margin of CSBR has grown nicely.
CSBR has a Gross Margin (48.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
Industry RankSector Rank
OM 5.29%
PM (TTM) 5.19%
GM 48.47%
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

3

2. Health

2.1 Basic Checks

CSBR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CSBR has more shares outstanding than it did 1 year ago.
CSBR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CSBR has a worse debt to assets ratio.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

CSBR has an Altman-Z score of 0.45. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.45, CSBR is doing worse than 71.43% of the companies in the same industry.
The Debt to FCF ratio of CSBR is 0.03, which is an excellent value as it means it would take CSBR, only 0.03 years of fcf income to pay off all of its debts.
CSBR has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. CSBR outperforms 92.86% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that CSBR is not too dependend on debt financing.
The Debt to Equity ratio of CSBR (0.02) is better than 66.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.03
Altman-Z 0.45
ROIC/WACC2.91
WACC10.42%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

CSBR has a Current Ratio of 0.93. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.93) is worse than 91.07% of its industry peers.
A Quick Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.93, CSBR is doing worse than 83.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

6

3. Growth

3.1 Past

CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 289.47%, which is quite impressive.
The Earnings Per Share has been growing by 146.62% on average over the past years. This is a very strong growth
Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 10.11% in the last year.
The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%

3.2 Future

Based on estimates for the next years, CSBR will show a very negative growth in Earnings Per Share. The EPS will decrease by -41.69% on average per year.
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 18.26% on average per year.
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6

5

4. Valuation

4.1 Price/Earnings Ratio

CSBR is valuated rather expensively with a Price/Earnings ratio of 18.02.
Based on the Price/Earnings ratio, CSBR is valued cheaper than 87.50% of the companies in the same industry.
When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (27.40), we can say CSBR is valued slightly cheaper.
CSBR is valuated quite expensively with a Price/Forward Earnings ratio of 42.40.
CSBR's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.94. CSBR is valued rather expensively when compared to this.
Industry RankSector Rank
PE 18.02
Fwd PE 42.4
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CSBR is valued cheaply inside the industry as 80.36% of the companies are valued more expensively.
96.43% of the companies in the same industry are more expensive than CSBR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.42
EV/EBITDA 17.62
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The decent profitability rating of CSBR may justify a higher PE ratio.
CSBR's earnings are expected to decrease with -41.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.69%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CSBR!.
Industry RankSector Rank
Dividend Yield N/A

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (10/17/2025, 4:04:02 PM)

6.487

-0.07 (-1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)09-15 2025-09-15/amc
Earnings (Next)12-09 2025-12-09
Inst Owners48.17%
Inst Owner Change0%
Ins Owners26.06%
Ins Owner Change0%
Market Cap89.46M
Analysts82.86
Price Target12.24 (88.69%)
Short Float %0.9%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.88%
Min EPS beat(2)65.69%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1095.34%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)599.88%
EPS beat(12)8
Avg EPS beat(12)365.32%
EPS beat(16)10
Avg EPS beat(16)266.15%
Revenue beat(2)2
Avg Revenue beat(2)1.19%
Min Revenue beat(2)0.83%
Max Revenue beat(2)1.54%
Revenue beat(4)4
Avg Revenue beat(4)8.21%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)6
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)0.98%
Revenue beat(16)10
Avg Revenue beat(16)1.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-87.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.56%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-1.82%
Valuation
Industry RankSector Rank
PE 18.02
Fwd PE 42.4
P/S 1.57
P/FCF 12.42
P/OCF 11.72
P/B 25.5
P/tB 28.19
EV/EBITDA 17.62
EPS(TTM)0.36
EY5.55%
EPS(NY)0.15
Fwd EY2.36%
FCF(TTM)0.52
FCFY8.05%
OCF(TTM)0.55
OCFY8.53%
SpS4.12
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.66%
ROE 84.15%
ROCE 38.35%
ROIC 30.3%
ROICexc N/A
ROICexgc N/A
OM 5.29%
PM (TTM) 5.19%
GM 48.47%
FCFM 12.66%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.86
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.03
Debt/EBITDA 0.01
Cap/Depr 28.08%
Cap/Sales 0.76%
Interest Coverage 250
Cash Conversion 167.47%
Profit Quality 243.9%
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z 0.45
F-Score7
WACC10.42%
ROIC/WACC2.91
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y199.05%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-7.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y375.86%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y4141.67%
OCF growth 3Y4.35%
OCF growth 5Y20.48%